Rheumatoid Arthritis: An Updated Overview of Latest Therapy and Drug Delivery

Disha Kesharwani¹, Rishi Paliwal², Trilochan Satapathy¹, Swarnali Das Paul³*

¹Columbia Institute of Pharmacy, Raipur, Chhattisgarh, India
²Assistant Professor, Faculty of Pharmacy, IGNTU, Amarkantak, Madhya Pradesh, India
³Associate Professor, Faculty of Pharmaceutical Sciences, SSTC, SSGI, Bhilai, C.G, India

Key Words
Arthritis, Cytokines, Disease-modifying anti-rheumatic drugs, TNF-α Interleukins, abatacept, rituximab, glucocorticoid.

Abstract

Rheumatoid arthritis is a severe autoimmune disorder, related to joints. It is associated with serious cartilage destruction. This causes disability and reduces the excellence of life. Numerous treatments are existed to combat this disease, however, they are not very efficient and possess severe side effects, higher doses, and frequent administration.

Therefore, newer therapies are developed to overcome all these limitations. These include different monoclonal antibodies, immunoglobulins, small molecules used for immunotherapy and transgenes for gene therapy. One of the main goals of these new generation therapeutics is to address the underlying distressing biological processes by specifically targeting the causative agents with fewer systemic side effects and greater patient console. It is very fortuitous that loads of progressive investigations are going on in this field and many of them have entered into the successful clinical trial. But till date, a limited molecule has got FDA clearance and entered the market for treating this devastating disease.

This review highlights the overview of conventional therapy and advancements in newer therapeutics including immunotherapy and gene therapy for rheumatoid arthritis. Further, different novel techniques for the delivery of these therapeutics of active and passive targeting are also described.

1. Background

The word arthritis came from the Greek word "for joint inflammation". It mainly affects the joints of the body. But sometimes other tissues of the body, such as the kidneys, eyes, skin, etc. are also getting affected [1]. Arthritis belongs to the category of T cell-mediated autoimmune disorder in which the immune system of the body attacks its own tissues. It is a disease in which the body fails to recognize the self-molecules from foreign molecules [2].

In rheumatoid arthritis, the immune responses influence the secretion of rheumatoid factors and evoke destruction of cartilage and bones in progression. Both the environmental factors and genetic factors are implicated in the progress of clinical indication of RA [2-4]. Joint damage occurs due to the auto-reaction of different immune modulators like effector cells and cytokines. It starts at membranes of synovi- um and then progressively attacks the adjacent structures. The activation of dendritic cells, T cells, plasma cells, B cells, mast cells, macrophages, and angiogenesis cause sinusitis [5-6]. Amongst these, persistently...
activated synovial macrophages are one of the leading factors for producing inflammation in RA. Fig. 1 explains the progression of rheumatoid arthritis. However, the intensity of inflammation on the joints and degradation of tissues depends on the number and level of macrophage activation[6- 7]. Therefore, over the last few decades, the RA treatment has been progressed by considering its internal mechanisms so that drugs can be developed to target at the molecular level. Table 1 depicts different molecular targets explored for drug targeting [8-11].

These novel targeted drugs have proved the enormous potential for countering disease. However, distinguished side effects, long-term treatment challenges and cost of treatment are till have to be considered. The most important reason behind this is the nonspecific delivery of drug molecules. So nowadays the research is turned towards the development of targeted delivery strategies to the inflamed joints [12]. Although intra-articular injection is one of the best options as targeted therapy, repeated joint needling limits its utility which enhances the risk of infection. As well as it offers the local administration of the inflamed joints this cannot be a choice in case of polyarthritis and systemic disease [13]. The detailed study of inflammatory diseased tissue shows an abnormal increment of macrophages and other cellular factors. This leads to enhancing the targeting of therapeutics by different novel delivery techniques. These targeted delivery systems accumulate passively into inflamed tissues via different mechanisms like the enhanced permeability and retention, surface conjugation with a ligand and others. Surface conjugation helps in the active attachment to receptors which are proliferated by affected cells so that systemic side-effects can be reduced and efficacy can be increased[14-15].

In this review, the overview of conventional drugs for RA and advancements in the newer therapies as medical options for management are discussed. Clinical trial updates of different treatment are also reviewed and special consideration is given to different novel delivery systems for their delivery.

2. OVERVIEW OF CONVENTIONAL RA THERAPEUTICS

The present-day treatment for RA can be classified into four classes:

i. Non-steroidal anti-inflammatory drugs (NSAIDs)
ii. Glucocorticoids
iii. Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)
iv. Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)

These recognized therapies are summarized in Table 2. Under each section the mechanism of action, side effects, dose and new drug candidates of each class of the drug. Different NSAIDs are generally the first choice of drugs for the treatment of RA as well as for osteoarthritis and other musculoskeletal disorders. They are generally used for the symptomatic relief of the disease and do not have any effect on the cause of the disease. These drugs reduce pain and swelling by inhibiting the cyclooxygenase enzyme which is responsible for inflammation. Cyclooxygenase -1 and Cyclooxygenase -2 are the two isoforms of the enzyme [16-17]. Corticosteroids are the second leading prescribed drug for the treatment of RA. These agents possess strong anti-inflammatory effect as well as analgesic effect. An established Guideline for RA known as "National Institute for Health and Clinical Excellence (NICE)" states that corticosteroids should be used only after the application of all other treatment options and after gaining the complete knowledge about the side effects as these drugs produce severe osteoporosis and fractures, Cushing’s syndrome, weight gain, cataract, hypertension, etc. [18-19].

DMARDs are the drug of choice for RA treatment. These drugs mainly work on the progression of the disease, hence agents prevent further joint destruction and loss. This therapy has been found successful in many cases. It eliminates the need for any other treatment. Other drugs can be used for symptomatic relief until the completion of therapy [20-22]. Mainly the biologic and non-biologic disease modifying anti-rheumatic drugs (DMARDs) are the important pharmacological therapies for RA. DMARDs of non-biologic origin is also popular as small molecule DMARDs or low molecular weight DMARDs and a wide variety of chemically diverse drugs are in this group. These drugs are further divided into two classes: traditional and novel. In this section, only traditional DMARDs will be discussed. Traditionally DMARDs have been used since the 1920s are
### Table 1 Molecular Targets in Rheumatoid Arthritis

| S. No. | Molecular Targets | Role | Occurrence | Example of Targeting Drugs |
|--------|-------------------|------|------------|---------------------------|
| 1.     | Cyclooxygenase   | Pathway: Biosynthesis of prostanooids, biologically active substances, involved in pathological conditions inflammation. | Cytosol and tissue | Celecoxib, Piroxicam, Naproxen, Valdecobib |
| 2.     | Tumor Necrosis Factor-α | Activation of macrophages, synovial fibroblasts, endothelial cells, MMPs and adhesion molecule expression and release of other cytokines and PGs. | Synovial fluid and tissue | Infliximab, Etanercept, Adalimumab, Golimumab, Certolizumab pegol |
| 3.     | Interleukin-1 | Potent inducer of MMPs, eicosanoids, and receptor activator of NF-κB Ligand, Hyaline cartilage synthesis inhibitor. | Synovium | Anakinra |
| 4.     | Interleukin-6 | Activation of osteoclasts, bone resorption, upregulates intercellular cell adhesion molecules 1 expression. | Serum and synovial fluid | Tocilizumab, lactoferin |
| 5.     | Interleukin-8 | -- | Synovium | ABX-IL8 |
| 6.     | Interleukin-10 | Inhibit the production of cytokines and Enhancement of production of IL-1RA | Synovial tissue | |
| 7.     | Interleukin-12 | Act in synergy with anti-TNF-α antibodies | Synovial fluid | ADT-874 |
| 8.     | Interleukin-15 | Activates T-cells, Stimulation of macrophages to release TNF-alpha | Joint | HuMax-IL-15 |
| 9.     | Interleukin-17Alpha | Activation of IL-1, b and IL-6, implicated in osteoclast activation causing bone resorption in RA | Synovium | -- |
| 10.    | Interleukin-18 | IL-1 and TNF production enhancement | Synovium | IL-18bp |
| 11.    | Matrix Metalloproteinase | Involved in bone and cartilage degradation | Joint | Trocade (Ro 32-3555) |
| 12.    | Nuclear Factor-κB | -- | Cytosol | Igaratimod |
| 13.    | Cathepsin B | Cleaves aggrecan and enhancement of RA | Synovial tissue | -- |
| 14.    | Aggrecan | Maintenance of cartilage integrity | Synovium | -- |
| 15.    | Osteopontin | Stimulates cell adhesion, migration, and specific signaling function. | Extracellular fluid, and inflammation site | |
| 16.    | Prostaglandin (PG) | Bone resorption stimulator | Osteocyte | Celecoxib, Piroxicam, Naproxen, Valdecobib |
| 17.    | JNK MAPKs | Inhibition affects TNF production | Synovial tissue | Pamaptimod, VX-702 and S630-469 |
| 18.    | Osteoclastin M | Synergistic with IL-1, promote cartilage damage | Synovial fibroblasts | -- |
| 19.    | Collagen I | Osteoblastic differentiation of the bone marrow cells | Bone cell | -- |
| 20.    | Collagen II | Maintain the integrity of cartilage | Cartilage | -- |
| 21.    | T lymphocyte | Essential for the continued activity of inflammation in RA | Thymus | Abatacept |
| 22.    | B lymphocyte | Antigen presentation | Bone marrow, synovial membrane | Rituximab |
| 23.    | Janus Kinase (JAK) | Affect intracellular signaling through their association with transcription factors known as STATs | Synovium | Tolctacinib, VX-599, Baricitinib (formerly LY3009104/ INCB028010), Ruxolitinib (formerly INCB018424) |
| 24.    | Spleen Tyrosine Kinase (Syk) | Syk is theoretically connected to inflammation and bone resorption. | Synovium | Tolstatimab (formerly R406, R788 is the prodrg). |
Table 2 Overview of Conventional RA Therapeutics

| S. No. | Category        | Drug        | Brand name | Adult Dose                                      | Mechanism                          | Side effects                                                                 | Company                        | FDA Approval |
|--------|-----------------|-------------|------------|------------------------------------------------|------------------------------------|-------------------------------------------------------------------------------|--------------------------------|--------------|
| 1.     | NSAIDs          | Celecoxib  | Celebrex   | Tablet 100 to 200 mg orally twice daily.      | COX-1 and COX-2 inhibitor         | Dyspepsia, peptic ulcer disease, bleeding, myocardial infarction, Increased Blood pressure, Heart failure. | G.D. Searle                      | FDA 1998     |
|        |                 | Piroxicam  | Feldene    | 20–4-mg daily                                  |                                    |                                                                               | Pfizer                          | FDA 1982     |
|        |                 | Nabumetone | Relafen    | 1000 mg daily                                  |                                    |                                                                               | Teva Pharmaceuticals Ltd.      | FDA 2000     |
|        |                 | Naproxen   | (i) Anaprox (ii) Neprelan | 500-1000 mg daily 375 mg, 50 mg daily       |                                    |                                                                               | Atmahs Pharma Inc.             | FDA 1980     |
|        |                 | Etodolac   | Lodine     | 100–200 mg not more than 1000 mg/d day       |                                    |                                                                               | Teva                            | FDA 2000     |
|        |                 | Rofecoxib  | Vioxx      | 25 mg Daily                                    |                                    |                                                                               | Merck                          | FDA 2002     |
|        |                 | Valdecoxib | Bextra     |                                                |                                    |                                                                               | Pfizer                          | FDA 2001     |
|        |                 | Ibuprofen  | (and Famotidine) Duexis | 800 mg/26.6 mg                               |                                    |                                                                               | Horizone Pharma                | FDA 2011     |
|        |                 | Prednisone | Deltasone, Liquid Pred, Sterapred | 5-60 mg/day in divided doses | Inhibition of macrophage accumulation, reduction of capillary permeability | Osteoporosis Stomach ulcer Increased blood pressure Irritability and/or excitability Increased blood sugar/glucose Cataracts (clouding of eye lenses) | Pharmacia and UP John          | FDA 1955     |
|        |                 | Methyl Prednisone | Depopred, Medrol, Methacort, Predacorten | 2-60 mg/day |                                    |                                                                               | Hospira                         | FDA 2006     |
|        |                 | Hydrocortisone | A-Hydrocort, Cortef | 10-320 mg/day |                                 |                                                                               | Merck                          | FDA 1958     |
|        |                 | Dexamethasone | Decadron, Dexpak, Hexadrol, Taperpak | 0.75 – 9 mg/day |                                 | Inhibition of aminomimidazole carboxamide ribonucleotide (AICAR) transformylase and thymidylate synthetase | Silvergate Pharmas             | (i) FDA 2001 |
|        |                 | Methotrexate | (i) Trexall (ii) Xatmep | Maximum weekly dose: 20 mg. |                                    | Nausea, mouth ulcer, hair loss, cytopaenias, elevated liver enzymes, rarely pneumonitis | Silvergate Pharmas             | (ii) FDA 2017 |
mainly non-biologic. They are including Sulphasalazine, Chloroquine, Methotrexate, Azathioprine, Cyclosporine A, Minocycline, and others. Even in the new era of biologic, methotrexate (MTX) still remains the drug of choice for RA and prepared as a standard to probate many other new disease-modifying drugs.

Novel Non-biologic DMARDs are further divided into four classes: phosphoinositide 3-kinases (PI3Ks) inhibitors, glycosidase inhibitors, matrix metalloproteinases (MMPs) inhibitors and cathepsin inhibitors [23].

2.1. Current FDA status of conventional RA therapeutics

It is very unfortuitous that till 2017 only 25 (approx) drugs got approval for the RA treatment by the Food and Drug Administration (FDA). These drugs include corticosteroids, NSAIDs, different antibodies, and immunoglobulins. Methotrexate is one of the prime and vintage RA drugs of the mainstays for its dual capacity to reduce pain-swelling and modify joint damage to prevent disease progression over time. Methotrexate was first applied in 1947 as folate antagonist in pediatric leukemia. In 1951, its effect on RA was established by Gubner and it got approved by the FDA in 1988. In the last 25 years, this drug has become a primary standard in the treatment of adult RA. Another pioneer drug prednisolone or methylprednisolone was the drug of choice in RA in most chronic cases and to date, they are in the system. The FDA approved methylprednisolone in October 1957 for treatment of RA [24].

The approval of Lodine by Wyeth containing etodolac was a remarkable confrontation in the year 1996. Immediately after that Azulfidine enteric coated tablets of sulfasalazine and Naprelen containing naproxen came into the market in the same year. However, sulfasalazine was permitted for medical application in 1950 in the United States. Initially, this drug was formulated as an enteric-coated formulation marketed as AZULFIDINE EN-tabs. These tablets were specifically intended to control nausea and stomach upset. Till date, this tablet is the only FDA approved formulation of sulfasalazine for the treatment of both juvenile and adult RA [25-27].

In the year of 1997, the first generic equivalent of Lodine came into the market just after one year by Royce Laboratories was Etodolac. Another three NSAIDS got approval in this year: Arthrotec by Searle, Ketoprofen by Schein Laboratories was Etodolac. Another three NSAIDS got approval in this year: Arthrotec by Searle, Ketoprofen by Schein Pharmaceuticals which is a generic equivalent or Oruvail and Tolmetin Sodium by Teva Pharmaceutical [28-29].

Hoechst Marion Roussel company launched Arava containing Leflunomid tablet in 1998. Leflunomide is an immunosuppressive disease-modifying antiarthritic drug, used in RA and psoriatic arthritis [30]. In 2001 Valdecoxib (NSAIDs) tablets under the brand name Bextra got approval launched by Pharmacia Pfizer. However, because of the increased risk of heart attack and stroke, it was removed from the U.S. market in 2005. The same incidence

table

| S. No. | Category | Drug | Brand name | Adult Dose | Mechanism | Side effects | Company | FDA Approval |
|-------|----------|------|------------|------------|-----------|-------------|---------|--------------|
| 1.     | CTX      | Leflunomide | ARAVA      | Initial dose: 100 mg orally once a day for 3 days | Inhibits T-cell proliferation and production of autoantibodies by B cells. | GI disturbance, hair loss, weight loss, rash and itch, mouth ulcer, headache, cytopenias, hypertension | Sanofi Aventis US | FDA 1998 |
| 2.     | CTX      | Sulfasalazine | AZULFIDINE | 0.5-2 gm/day | Inhibits the release of inflammatory cytokines | Nausea, abdominal pain, hair loss, cytopenias, elevated liver enzymes, agranulocytosis, skin rashes | Pharmacia & Upjohn | FDA 1996 |
| 4.     | Biologic DMARDs | Tocilizumab | ACTEMRA | Dose - 4 mg/kg followed by an increase to 8 mg/kg | Inhibits Interleukin – 6 receptor | Upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased AL, injection site reactions | Genentech | FDA 2017 |
| 5.     | Biologic DMARDs | Golimumab | SIMPONI | Dose - 50 mg | | | Centocor Ortho Biotech | FDA 2009 |

| Company | FDA Approval |
|---------|--------------|
| Sanofi Aventis US | FDA 1998 |
| Pharmacia & Upjohn | FDA 1996 |
| Genentech | FDA 2017 |
| Centocor Ortho Biotech | FDA 2009 |
also happened with Vioxx containing rofecoxib drug (approved April 2002, withdrawn October 2004) [31-32]. After a long gap in 2010, VimoHo a combination product of naproxen and esomeprazole by AstraZeneca got permission for RA in patients at threat for NSAID linked ulcers [33]. In 2011, another combination product of ibuprofen and famotidine got approved under the name Duxis for the relief of RA as well as osteoarthritis by Horizon Pharma. It was also indicated for gastric ulcers associated with therapy. By this time, many monoclonal antibodies, immunoglobulins got the green signal from the FDA for treating this devastating disease state. Immediately after one year, in 2012 delayed-release tablets of prednisone (Rayos) get underway by Horizon Pharma for curing different inflammatory diseases, including rheumatoid arthritis, psoriatic conditions, COPD, and asthma [34].

3. ADVANCES IN NEW GENERATION RA THERAPEUTICS

The autoimmune characteristics of RA which is primarily evident as ‘chronic inflammatory arthropathy’, create this treatment challenging for years. Conventional drugs have no (NSAIDs) or limited (Corticosteroid) authority on this autoimmune nature of the disease. Moreover, corticoids and other non-biologic DMARDs are inadequate and only capable of achieving clinical remission in combination. Further, they possess common unwanted side effects such as stomach upset, nausea, vomiting, diarrhea, liver problems, etc. In addition to this, approximately half of the RA patients don’t show any promising reaction to traditional DMARDs [21].

Thus, one of the foremost goals of new generation RA therapies is to repress the fundamental biological processes which cause bone erosion, joint destruction, and progression of physical comorbidities. These medicines have a fast therapeutic action and possess comparatively less systemic side effects than former treatments. Most significantly, these therapeutic substances can modify the fundamental cause of inflammation and cell damage. These amazing therapeutic agents are including biologic DMARDs or biotech drugs used in immune therapy and specific transgenes for gene therapy [21]. In this section, introduction, advancements, clinical aspects and other details of these newly introduced agents have been discussed.

3.1. Immunotherapy for RA

The amendment of immune therapies as especially do target the molecules and cells accountable within the immunopathogenesis is very essential for RA treatment. The preceding endeavors at RA immunotherapy had been cells targeted rather than molecules. The detected T lymphocyte values into the investiture about RA resulted in endeavors according to alternate the immune replication by denotes of depleting T lymphocytes [35]. However, this method was once generally unfruitful. It was found rational to aim at T cells, so those hold a sanctioned role among initiates or directing immune replications. During this length, many other researchers have been focused on provocative cytokines, along a most important attempt focused regarding the provocative TNF-α. At the beginning of the 1980s, TNF-α was recognized in the synovial film of RA patients. 27 years later in 1980s new TNF-α blockers had been produced. The drug named CA2 (infliximab) was first in this category.

Last study of few years shows that many patients impulsive to established therapies have proved effective in treatment with novel biological agents. The rationale behind this may be the efficiency of highly specific targeting approach to provocative cytokines and other involved cells and along with their surface molecules in the RA pathogenesis. They mainly act by three mechanisms:

First, prevention of binding of the cytokines to its cell-surface receptors in different ways, including monoclonal antibodies, soluble receptors, and natural antagonists. Second, inhibition of production/proliferation of provocative cytokines by anti-inflammatory cytokines such as interleukin-4, 10 or 13. Third, exclusion of the inflammatory cells or interference with cell function by targeting either biological agent against differentiation or cell-surface antigens attached functionally.

Presently used biologic DMARDs are including TNF antagonists (etanercept, infliximab, golimumab, adalimumab), IL-1α and IL-6 inhibitor (tocilizumab), T cell inhibitors (abatacept), B cell inhibitors, anti CD20 (Rituximab). However, latest biologic DMARDs under investigation are phospholipase A2 (PLA2) inhibitors, vascular endothelial growth factor (VEGF) inhibitors, chemokines blocker, colony stimulating factor” (CSF) inhibitors and others [36].

Amongst recently used DMARDs TNF blockers are much more extravagant and consequently payers endeavor to restrain their exploitation of patients whose disease cannot otherwise be controlled. Therefore, traditional therapy is a junction point in RA treatment where cost considerations become very authentic. While biologic therapies are efficacious, they are sumptuous. The alternative approach of amalgamation therapy with conventional DMARDs, such as hydroxychloroquine and sulfasalazine together with methotrexate (soi-disant “triple therapy”) and the utilization of glucocorticoids as bridge therapy, is additionally efficacious. It is much less extravagant, but it involves several medicines and the insertion of glucocorticoids and their associated side effects [37].

3.1.1. Current FDA status of immune-therapeutics

Table 3 depicts the FDA approved immune-therapies for RA with their mechanism and side effects. Initially, Enbrel (Etanercept) was launched in November 1998. It was the first targeted biologic for RA. It reduces the symptoms and inhibits the progression of structural damage in patients facing moderate to highly active rheumatoid arthritis. It is also useful in juvenile polyarticular type RA. It is basically a TNF antagonist. Further, in January 2002, it received approval for diminishing the symptoms of arthritis in pa-
| S. No. | Approval year | Brand name | Biologics | Company | Dosage form | Mechanism | Side effects |
|-------|---------------|------------|-----------|---------|-------------|-----------|--------------|
| 1     | November 1997 | Rituxan    | Rituximab | Genentech | IV solution | antiCD20 antibody | Skin Rashes |
| 2     | November 1998 | Enbrel     | Etanercept | Immunex Corporation | SC injection | TNF inhibitors | Serious infections including tuberculosis, upper UTI |
| 3     | November 2001 | Kineret    | Anakinra  | Amgen    | Injectable   | IL-1 receptor antagonist | Diarrhea, stomach pain, Headache |
| 4     | June 2002     | Remicade   | Infliximab | Centocor Ortho Biotech | Intravenous infusion | TNF inhibitors | Chest pain, sore throat, dizziness, fatigue |
| 5     | December 2002 | Humira     | Adalimumab | Abbott Laboratories | SC injection | TNF inhibitors | Brusing at the injection site, upper respiratory infection, nausea |
| 6     | December 2005 | Oencia     | Abatacept  | Bristol-Myers Squibb | SC injection | CTLA4-Ig fusion protein | Increase risk of serious infections, Skin irritation, itching rashes, swelling and pain |
| 7     | April 2009    | Simponi    | Golimumab  | Centocor Ortho Biotech | SC injection | TNF inhibitors | Increase the risk of serious infections including tuberculosis, |
| 8     | May of 2009   | Cimzia     | Certolizumab b pegol | UCB | SC injection | TNF inhibitors | Tuberculosis, UTI, headache |
| 9     | June 2009     | Ilaris     | Canakinumab b | Novartis | Powder for injection | anti-IL-1β receptor antibody | Bronchitis, Diarrhoea, Gastroenteritis, vertigo, weight increase |
| 10    | September 2009 | Stelara    | Ustekinumab b | Janssen Biotech | SC injection | Human IgG1k monoclonal antibody | Nasopharyngitis, diarrhea, upper UTI, nausea |
| 11    | January 2010  | Actemra    | Tocilizumab | Genentech | IV infusion | anti-IL-6 receptor antibody | Serious infections, elevated liver enzymes neutropenia, decreased platelet counts |
| 12    | November 2012 | Xeljanz    | Tofacitinib | Pfizer   | Tablet, extended release | Janus Kinase inhibitor | Upper respiratory tract infection, Diarrhoea, Nasopharyngitis |
| 13    | March 2014    | Otezla     | apremilast | Celgene  | Tablet | PDE4 inhibitor | Diarrhoea, nausea, headache |
| 14    | March 2016    | Taltz      | Ixekizumab | Eli Lilly | SC injection solution | Anti IL-17A receptor antibody | Injection site reactions, tinea infection, nausea |
| 15    | May 2017      | Kevzara    | sarilumab  | Sanofi   | SC injection | IL- 6 receptor antagonist | Neutropenia, increased ALT, injection site erythema, UTI |
tients with psoriatic arthritis for which it’s the first therapy [38].

Studies reported that TNF blockade is one of the most effective methods for RA treatment. It leads to the evolution of distinct inhibitors of TNF like Infliximab, Adalimumab, Certolizumab pegol, Golimumab. In June 2002, infliximab (IFX) came into the market. It is a chimeric monoclonal antibody (mAb) against TNF-α [39]. After six months another TNF-α blocker, Humira (adalimumab) by Abbott Laboratories got approval.

Anakinra (brand name Kineret) the first biopharmaceutical drug used to treat rheumatoid arthritis got approval in November 2001. It is a recombinant human receptor antagonist acting on IL- 1 and nonglycosylated form of protein.

A specific co-stimulation modulator named Abatacept is accepted in 2005. It binds to CD80/86 and inhibits T-cell activation and thus it modulates its interaction with CD28 which initiates, the co-stimulatory signal required for the T cell activation. This drug is suggested for patients not responding to different DMARDs or TNF inhibitors, takes an approach that differs from the TNF inhibitors [40].

It is notable that amongst these immune-therapeutics, etanercept, adalimumab, and anakinra are self-injectable drugs, while infliximab, rituximab, and abatacept are infused products [41]. A product of Novartis, Canakinumab (ACZ885, Ilaris) acts by neutralizing IL-1β signaling. It is a human anti-IL-1β monoclonal antibody. It suppresses inflammation in patients with autoimmune disorders [42]. STELARA® is a human IgG1k monoclonal antibody. It attaches specifically to the protein on p40 subunit and utilized by both the cytokines interleukin -12 and 23. STELARA® (ustekinumab) is prescribed to the patients of active psoriatic arthritis. A combined form of it and methotrexate is also frequently suggested [43].

Tocilizumab denoted as TCZ was the first biological DMARD and it targets to IL-6. The clinical trials for other inhibitors of Interleukin-6 are also in progress. These include sarilumab the monoclonal antibody (REGN88/SAR153191), and nanobody (ALX-0061), sirukumab, olokizumab, and MED15117. EVZARA targets and binds with high affinity to IL-6 receptors (sIL-6R and mIL-6R) came into the market in 2017 [44].

Janus kinase pathway inhibition is an advanced mechanism. It inhibits the intracellular effects of several inflammatory cytokines and completely modulates the immune and inflammatory response. Tofacitinib is the first oral non-biologic DMARD, approved in 2012. Baricitinib is another one from the same group. For the patients with an unsuccessful DMARD history tofacitinib is the best drug [45].

3.2. Gene therapy for RA

In the understanding of the molecular mechanisms behind RA pathogenesis cause a continuous advancement over the past years. It results in the development of many kinds of targets of novel gene therapy. It is an established fact that RA pathogenesis is involved with activation of specific T cells, osteoclasts, monocytes, fibroblasts, B cells, endothelial cells and macrophages [46]. Along with this excess production of pro-inflammatory factors like cytokines and chemokines, rheumatoid factor and matrix metalloproteinases are also responsible. Each of these factors can be manipulated as a target in multiple ways using gene therapy. This section presents a review of the latest advances in gene therapy for RA treatment.

The therapeutic genes are generally delivered by two methods: in vivo and ex vivo. These methods can accomplish the need of local as well as systemic delivery of genetic material. Generally, the intraarticular route is used for gene transfer in local in vivo strategies [47]. However, ex vivo strategies include three steps:

i. Exclusion of synoviocytes from the affected area usually joint
ii. In- vitro Transduction
iii. Transduced cells are re-injected into the joints.

The systemic gene therapy consists of the transfer of genes to the cells and these cells synthesize the gene product. These gene products are then secreted into the circulation. This approach is beneficial as rheumatoid arthritis has its systemic nature and it has the capacity to target more than one joint simultaneously. This also leads to non-specific immune suppression with increased susceptibility to infection [48]. Many transgenes are available which are utilized for RA in different methods some of the important examples are summarized here.

In a report ‘IL-1 Ra’ transgene was introduced by naked DNA method to DBA/1 mice. Arthritis was induced by using an adjuvant-induced arthritis method. Four sites of hind limbs were injected intramuscularly. The results depicted that the onset of collagen-induced arthritis was completely prevented with decreased synovial inflammation, cartilage destruction, with a lesser expression of IL-1β in ankle joints [49].

One more study administered ‘IL-1 Ra co-expressed with GFP’ by i.e. injection into mice via adenovirus. The results reveal the severity of arthritis was reduced along with reduced foot-pad swelling, inflammatory cell infiltration, and synovial proliferation. Additionally, it increased Th1 driven IgG2a antibodies and Th2 driven IgG1 antibody and conserved the proteoglycan concentration [50]. It was observed that impedance in enduring provocative autoimmune disease after intravascular tail injection of a single-chain antibody into ‘DBA/1 LacJ’ mice [51]. A study on ‘adoptive cellular gene therapy’ where T-cell was hybrid and transduced with RT administered CIA by intravenous tail injection. They reported transgene expression was constrained to the paw and decreased the level of IL-6 [52]. One more study conducted on both IL-1Ra and sIL-1RACP. They were injected CIA by i.v. Via adenovirus into DBA/1 mice. The result disclosed sIL-1RACP refurbished CIA without affecting T cell immunity, whereas IL-1Ra refurbished CIA and repressed lymphocyte propagation [53]. In a motivating study, researchers used variants of hTNFRIIs as monomeric, dimeric and ‘chimeric hTNFRIs/mIgG1’ type. These were introduced via ET of plasmids DBA/1 mice, CIA by intramuscular injection. Researchers found hTNFRIIs/mIgG1 at the beginning of CIA condensed clinical and histological manifestations of the disease. Dimeric form demonstrated the effective-
ness of local expression in a dose-dependent manner and lasted a minimum of 6 months. Researchers found after intraarticular injection of an adenovirus (over-expressing IL-18BP) to mouse knees before the sign of CIA offer many favorable effects on the course of RA disease. These include the control incidence of bone damage, occurrence of disease, and collagen II-specific IgG2a antibody levels [54].

In RA patients 08 clinical trials of gene therapy have been initiated. One of these clinical trials was closed that was aimed to conduct genetic synovectomy, due to inadequate enrollment. The only clinical trial data on rheumatoid arthritis have published by Evans and coworkers. It came from a phase 1 protocol of arthritic patients. This data approved the safety and ease of gene transfer to arthritic joints [55].

4. ADVANCES IN DRUG DELIVERY SYSTEMS FOR THE RA THERAPEUTICS

Despite the presence of a wide variety of therapeutics for RA, the major challenge lies in their successful delivery to the affected area. Along with this, most of these therapeutics often cause side effects and drug resistance. The most important reason behind this is the nonspecific delivery of drug molecules. So nowadays the research is turned towards the development of targeted delivery strategies to the inflamed joints [41]. The changed properties of the inflammatory site, such as a change in pH, temperature, EPR effect and overexpression of various cells have the greatest potential for targeting. Therefore, different delivery systems are establishing their arena by targeting the drug to the site, reducing the amount of drug and adverse effect [56], Fig. 2 shows some novel carriers used and fig. 3 illustrates the mechanism of different newer delivery systems for targeting RA. Advancements of these delivery systems and their efficacy in carrying the therapeutic molecule to the target site are described here.

4.1. Nanoparticles

Nanoparticles are the particles microscopic in size and smaller than 1 micron. They generally measure approximately 1 - 1000 nm in size and differ their properties from their macroscale forms. The drug can be embedded in the nanoparticles matrix or it can be adsorbed onto the surface. Nanoparticles also enhance the solubility and bioavailability of poorly soluble drugs. These nanocarrier systems also have properties of the high surface to volume ratio, enhanced permeability and retention effect, sustained action, etc. similar to other nanocarriers [56-57]. Due to these unique properties, they are successfully used for drug targeting in different diseases including RA.

Solid Lipid Nanoparticles (SLN) are suitable colloidal carriers. These are used for delivery of poorly soluble drugs. These colloidal carriers are differentiated from nanostructured lipid carriers (NLC) by the composition of the solid matrix. They are alternative carriers to liposomes and emulsions. As the SLN are prepared from biocompatible and biodegradable lipids, these systems are highly acceptable and tolerable. The lipid nanoparticles are the safest nano-carrier system [58].

Lee et al., 2013 have developed half-shelled gold nanoparticles attached with Arginine- Glycine- Aspartic peptide (RGD) for RA treatment. The active constituent was methotrexate. Methotrexate belongs to DMARDs class of antirheumatic drugs. RGD peptide was used as a ligand for targeting the inflamed tissue. They concluded that the prepared nanocarrier system minimized the adverse effects of methotrexate and enhanced its efficacy. On the basis of obtaining results, they suggested that this nano-carrier can also be used for the delivery of other DMARDs efficiently [59]. Satya Prasad et al., 2016 explained that multifunctional nanoparticles are used for Rheumatoid arthritis or other inflammatory diseases. They described the Zinc oxide and Zinc sulfate nanoparticles, gold nano compounds such as auranozin, aurothioglucose, silver nanoparticles, and metallic copper nanoparticles were used to improve the clinical status of arthritic patients.
They concluded that GOLD nanoparticles are the best remedy for rheumatoid arthritis [60]. Hwiwon Lee et al., 2014 prepared hyalurionate gold nanoparticles and Tocilizumab complex for rheumatoid arthritis treatment. Gold nanoparticles are used as a carrier with an antiangiogenic effect. The effect of the complex was approved by ELISA and western blot analysis in mice using adjuvant-induced arthritis [61]. Homma et al., 2010 told that Hyaluronic Acid (HA)- conjugated methotrexate (MTX) nanoparticles reduced the proliferation of fibroblast-like synoviocytes (FLs) in vitro, and symptoms of arthritis were consequently alleviated [62]. Zheng et al., 2015 successfully prepared oil, water nanoemulsion of curcumin for improving the low oral bioavailability of curcumin, which can facilitate the formulation of oral dosage forms [63]. Shailaja A.K. et al., 2016 prepared polymeric nanoparticles containing Mefenamic acid. They used the ionotropic gelation technique. After the development of the nanoparticles, they characterized these nanocarriers and found that these systems possessed excellent properties such as less particle size, greater stability and controlled drug release for 12 hours [64]. Pang-hu Zhoua et al., 2018, synthesized hyaluronic acid-chitosan nanoparticles containing plasmid DNA encoding Cytokine response modifier A (HA/CS-CrmA). They used the method of complex coacervation of cationic polymers. The nanoparticles qualified different evaluation parameters. The result showed that the prepared nanoparticles safely transfected arthritic cells and released the drug with sustained effect. It can be concluded that the prepared nanoparticles prevent cartilage destruction and inflammation [65]. Wenshuai Fan et al., 2018, used kertogenin (KG) molecule that is reported to show a protective and regenerative effect on cartilage, and polyurethane nanoparticles were prepared. The kertogenin conjugated polyurethane nanoparticles showed a sustained release of drug with regular spherical shape and size. The intra-articular (IA) injection of KGN conjugated polyurethane nanoparticles proved efficacious with less cartilage degeneration as compared to IA injection of plane KGN [66]. Jiesheng Ye <http://www.sciencedirect.com/science/article/pii/S0378517307008435> et al., 2008, studied in detail about SLNs loaded with actarit and incorporated in the intravenous injection formulation. Actarit is an anti-rheumatic drug with a poor water-solubility profile.

To improve the therapeutic efficacy of the poorly soluble drug and to reduce its nephrotoxicity and GIT disturbances were the primary objectives of the study. They concluded that actarit SLN in the form of injectable was promising passive targeting therapeutic agent for RA [67]. Antônio Luiz Boechat et al., 2015 developed MTX-Lipid core nanocapsules and MTX solution. They evaluated their efficiency for the reduction of inflammation. MTX-LNC were shown better results than the MTX solution for reducing different inflammatory agents. Along with this, they found that the nanocarrier system has reduced the dose of MTX. From the found results, they concluded that the LNC containing MTX are a very propitious system for treatment of inflammatory disorders [68]. Melling Zhoua et al., 2018, developed a targeted system of solid lipid nanoparticle (SLN) containing glucocorticoid prednisolone.

The SLN particles were coated with Hyaluronic acid (HA) shown as HA-SLNs/PD. Hyaluronic receptor CD44 found over-expressed on the surface of synovial lymphocytes, macrophages and fibroblasts in arthritic inflamed joints and HA efficiently binds to these receptors. The results showed that prepared nanoparticles (HA-SLNs/PD) accumulated and persisted longer in circulation. The formulation was found better in efficacy and safer than the free drug and from SLN of a drug without coating for the treatment of inflammatory disorders [69].

4.2. Liposomes

Liposomes are extensively used as drug carriers for rheumatoid arthritis treatment. They are basically vesicular concentric lipid bilayers. They enclose hydrophilic components inside them. They are highly biocompatible, biodegradable poses less toxicity and commercially important as they have the ability to entrap both the lipophilic and hydrophilic drugs [70].

Many drugs used for the treatment that RA possesses low bioavailability, limited selectivity, high clearance, etc. And that’s why to require frequent and high dosing to maintain the therapeutic effect. High doses are also the cause of side effects. Liposomes are the solution for these drawbacks. Weak pharmacokinetic profiles of many drugs can be improved by entrapping the drug in liposomes. They enhance the drug absorption too. Different types of liposomes possess different specific properties like large liposomes to show enhanced retention, small liposomes are good for passive targeting and PEGylated liposomes also enhance circulation time by reducing the uptake by the liver and spleen. By all these actions the localization of liposomes enhances by enhanced permeability and retention (EPR) effect [70-71]. William et al., 1995 developed liposomes containing methotrexate and compared its efficacy with the free methotrexate. They found that methotrexate containing liposomes have shown a significant effect on established arthritis. From the obtained results it can be concluded that the liposomal preparations show better results than the free drug [72]. Metselaar et al., 2003 developed PEG encapsulated liposomes containing glucocorticoids.

They followed single intravenous treatment and observed its effect on both the joint inflammation and cartilage destruction. They have also studied the targeting of these formulations to the inflammatory site. They concluded that the anti-inflammatory activity of glucocorticoids can be strongly enhanced by the development of long-circulating liposomes [73]. Prabhu et al., 2012 prepared and evaluate the methotrexate nano lipid vesicles for their antirheumatic activity. They successfully prepared methotrexate nano lipid vesicles with high efficiency, selectivity, and reduced toxicity [74]. Gottschalk et al., 2015 developed cationic liposomes containing MTX and compared their impact with the free MTX. They found that the liposomal MTX showed promising effects on inflamed sites than the free MTX [75]. Rahman et al., 2016 explained that over the conventional carriers, liposomal systems have many advantages related to the delivery of drugs, including merits.
in both passive and active targeting of drug molecules to the inflammatory sites [76]. Mengdi Jia et al., 2018 developed liposomal carriers to deliver dexamethasone and 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine by thin film hydration technique. The liposomal carriers for both the molecules were proved efficacious on the basis of results obtained. Both the formulation, taken together, a safe liposomal delivery system was developed to achieve inflammation targeted therapy against arthritis [77].

4.3. Polymeric micelles
These are self-assembled amphiphilic block polymers. They are biocompatible and biodegradable. They possess a hydrophilic shell and a hydrophobic core. The shell material generally utilized is polyethylene glycol. When polymeric micelles are compared with free drugs they show higher drug loading, stability and biocompatibility, circulation time and localization. Polymeric micelle is an ideal carrier system for both the passive and active targeted drug delivery as they improve the therapeutic window and reduce the toxic side effects. By using polymeric nanocarriers the Active Pharmaceutical Ingredients can be protected against biodegradation in the blood circulation and consequently the action can be prolonged. The drug molecules are directly and selectively delivered to the targeted area by using both active and passive delivery methods. Polymeric micelles show specific strength in solubilizing hydrophobic drugs and reduce the limitations associated with the toxic solvents [78-79].

Crielaard et al., 2012 developed novel derivatives of dexamethasone. These derivatives are covalently entrapped in polymeric micelles. They are hydrolytically cleavable and specially designed to achieve effective glucocorticoid targeting. The release rate of dexamethasone tried to be controlled by varying the degree of oxidation the thioether in the drug-linker [80].

Sethi et al., 2013 prepared sterically stabilized micelles (SSM) containing low doses of the vasoactive intestinal peptide (VIP) for the treatment of RA. The interaction of SSM and VIP protected the peptide from degradation and prolonged its retention time. The low doses of VIP in SSM can be vasoactive intestinal peptide a novel nanomedicine for RA. It was found that it can down-regulate both autoimmune and inflammatory components of RA [81].

4.4. Microemulsion / Nanoemulsion
Nanoemulsions are also known as mini-emulsion or submicron emulsions. It basically consists of oil in water type of emulsion. It possesses the droplet size of 100 - 500 nm. They are the good transporter for lipophilic compounds as they possess lipophilic core. They show good stability and clarity during storage. The property of possessing a low viscosity of nanoemulsions is beneficial for preparing sprays [82]. The small size of nanoemulsions provides properties such as high surface area per unit volume, stability, transparency, and tunable rheology. Generally, two methods are used to prepare nanoemulsions i.e. high energy and low energy method. Other methods include high-pressure homogenization, phase inversion, ultrasonication, bubble bursting method, etc.

Nanoemulsions come under ultrafine dispersion systems and their properties including visual, visco-elastic and targeting properties make them highly efficient novel delivery systems. Singh et al., 2017 & Pey et al., 2006, studied and optimized the composition and preparation method of nanoemulsions. They used a factorial design for the study. They concluded that the size of the droplets and the polydispersity affected by the variation in the composition and preparation methods. They have also used a central composite design for optimization [83-84]. Shakeel et al., 2008 examined the anti-inflammatory effect of celecoxib nanoemulsions. They compared the prepared transdermal preparation of celecoxib with conventional celecoxib gel on carrageenan-induced paw edema. They used ANOVA for the study. They found that the inflammatory response can be enhanced by using nanoemulsions.

They gave a conclusion that nanoemulsions can be successfully used for enhancing the anti-inflammatory effects of celecoxib [85]. Mello S B, et al., 2016 tested the anti-inflammatory efficacy of lipid nanoemulsions containing methotrexate given intravenously in rabbits with antigen-induced arthritis. They compared their formulation with marketed methotrexate. HPLC method was used for determining the pharmacokinetics of MTX nanoemulsions. They found the result that the uptake of methotrexate nanoemulsion was increased by two folds in arthritic joints. They concluded that the intravenously administered nanoemulsion was superior to the marketed preparation of MTX [86]. Modi et al., 2011 investigated the efficiency of aceclofenac nanoemulsion applied topically. They used the spontaneous emulsification method for the preparation of oil in water nanoemulsions. They used rat abdominal skin and determined topical permeation by Franz diffusion cell. They compared nanoemulsion gel with a conventional gel of aceclofenac. The result showed an increase in permeability parameters such as permeability coefficient, steady-state flux, etc. They concluded that nanoemulsion is potential delivery vehicles for aceclofenac when applied transdermally [87].

4.5. Nanogels
Nanogels are the polymeric delivery systems having size up to about 500 nm. Generally, nanoparticles are prepared and incorporated on the gel base. These systems possess the potential for targeting different types of drugs due to their small particle size, high biocompatibility, biodegradability high drug loading, good permeation capabilities, high water retention, etc [88]. Drugs from the nanogels can be delivered passively or actively. Nanogels are basically hydrogel that can accommodate a large amount of water inside them and swell to a large volume thus increasing the capacity to load a large amount of drug. Chen et al., 2013, Samah et al., 2010 prepared nanogel of methotrexate by surfactant-free emulsion polymerization meth-
and tested its permeation efficiency by Franz diffusion cells using a porcine ear skin. The presence of nanoparticles in the receptors was presented by the TEM study. They concluded that the enhanced permeation of the drug occurs due to the permeation efficiency of the nanogels [89-90]. Nagai, N., et al., 2015 prepared and evaluated the indomethacin nanogel ointment in adjuvant-induced arthritic rats. The indomethacin gel ointment was prepared by bead smash 12. The size of the nanoparticle of indomethacin was about 173 nm. They found the result that the increase in hind paw edema is reduced and the drug concentration in the affected tissues is increased by using nanogel ointment of the drug. They suggested by their findings that the use of nanoparticles, especially when applied topically avoids the unwanted side effects of any drug with a variety of advantages [91]. Khurana et al. 2013 formulated and evaluated the potential of meloxicam SLN incorporated in a gel base. The formulation was optimized by using various parameters. The skin permeation was determined using Franz diffusion cells and skin tolerance was determined in vivo by histopathological examination using mice. Car rageenan-induced rat paw edema method was used for determining the anti-inflammatory potential of the gel containing SLN. The result showed that nano-sized meloxicam SLN possesses controlled-release abilities with good permeation capacity. They gave a concluding remark that SLN gel can be used as an efficient delivery system for meloxicam for the alleviation of inflammatory diseases [92]. Elkomy et al., 2018 investigated the potential of SLN gel of tenoxicam and performed a pharmacokinetic Pharmacodynamic model for determining concentration-time profile in the skin. They used 23 factorial design to study the effect of different formulation variables on the properties of SLN gel for optimization. Gel tolerance was determined by using rabbit skin irritation test and the anti-inflammatory effect was determined by the rat paw edema model. They concluded that SLN-gel is a promising delivery vehicle for tenoxicam through the skin for arthritic disorder and PK-PD modeling is an efficient approach for indirect quantification of skin accumulation [93].

5. CONCLUSION

The pathophysiology behind rheumatoid arthritis (RA) is a complex milieu that, could not be fully described till date. However, the scientific workflow has explained several breakthroughs involved in the development of the disease. Despite this enormous advancement in the methods of treatment of the disease, there is still a lot of scope for further research as there is no therapy available which can completely cure the disease. Presently, maximum therapies work on symptoms of the disease. Along with this, they show poor efficacy, severe side effects, high doses, greater frequency of administration and high cost.

The novel drug delivery systems overcome many of the problems associated with conventional dosage forms. Passive and active targeting methods deliver the drugs directly to the inflamed site. In spite of these novel efforts, patients do not respond at all to the therapy in many cases. At present, a large number of researches of different drugs are reported to the management of rheumatoid arthritis, but a limited number of formulations entered into clinical trials. The field still requires prodigious study.

CONFLICT OF INTEREST

No conflict of interest

Reference

1. Klareskog L, Padyukov L, Lorentzen J, Alfredsson, L. Mechanisms of disease: genetic susceptibility and environmental triggers in the development of rheumatoid arthritis. Nat Clin Pract Rheumatol. 2006;2(8):425–33.
2. Lawrence T, Natoli G. Transcriptional regulation of Macrophage polarization: Enabling diversity with identity. Nat Rev Immunol. 2011;11(11):750–61.
3. Firestein GS. Evolving Concepts of Rheumatoid Arthritis. Nature. 2003;423 (6937):356–61.
4. Ferrari M, Onouha SC, Pitizalis C. Going with the flow: harnessing the power of the vasculature for targeted therapy in rheumatoid arthritis. Drug Discovery Today. 2016;21(1):172–9.
5. Wright HL, Moots RJ, Edwards SW. The multifactorial role of neutrophils in rheumatoid arthritis. Nat Rev Rheumatol. 2014;10:593–601.
6. Koenders MI, Vandenbarg WB. Novel therapeutic targets in rheumatoid arthritis. Trends Pharmacol Sci. 2015;36:189–95.
7. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part I. Arthritis Rheum. 2008;58:15–25.
8. William DA, Lemke TE. Non-steroidal anti-inflammatory drug. Foye’s Medicinal Chemistry. 5th ed. Philadelphia: Lippincott, Williams and Wilkins. 2006;751-93.
9. Claria J. Cyclooxygenase-2 Biology. Current Pharmaceutical Design. 2003;9(27):2177-90.
10. Ribbens C, Andre B, Kaye O, Kaiser MJ, Bonnet V, de Groote D. Increased synovial fluid levels of interleukin-12, sCD25, and sTNF-RI/sTNF-RI ratio delineate a cytokine pattern characteristic of immune arthropathies. Eur Cytokine Netw. 2000;11(4):669-76.
11. Yang L, Zhang J, Wang G. The effect of sodium hyaluronate treating knee osteoarthritis on synovial fluid interleukin-1β and clinical treat-men mechanism. Pak J Pharm Sci. 2015;28(1):407–10.
12. Moura CC, Segundo MA, Neves J, Reis S, Sarmento B. Co-association of methotrexate and SPIONs into anti-CD64 antibody-conjugated PLGA nanoparticles for theranostic application. Int J Nanomed. 2014;9:4911–22.
13. Mashaghi S, Jadidi T, Koenderink G, Mashaghi A. Lipid nanotechnology. Int J Mol Sci 2013;14: 4242–82.
14. Sehgal R. Nanotechnology and its applications in drug delivery. A review. Int J Mol Med. 2013;3:267.
15. Coco R, Plapied L, Pourcelle V, Jerome C, Brayden DJ, Schneider YJ, et al. Drug delivery to the inflamed colon by nanoparticles: Comparison of different strategies. Int J Pharm, 2013;440:3–12.

16. Schnitzer TJ, Truitt KRF. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Clinical Therapeutics. 1999;21(10):1688–1702.

17. Krug HLK, Broadwell MB, Delapp R, Palmer RH, Mahowald M. Tolerability and efficacy of nabumetone and naproxen in the treatment of rheumatoid arthritis. Clinical Therapeutics. 2000;22(1):40–52.

18. Hoes JN, Jacobs JW, Buttgerit F, Bijlsma JW. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol. 2010;6(12):693–702.

19. Buttgerit F, Doering G, Schaeffer A. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis. 2010;69(7):1275–80.

20. Smolen JS, Landewe R, Breedveld FC. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964–75.

21. McConkey B, Amos RS, Durham S, Forster PJ, Hubbell S, Walsh L. Sulphasalazine in rheumatoid arthritis. Br Med J. 1980;280:442–4.

22. Verstappen SM, Albada-Kuipers GA, Bijlsma JW, et al. A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Ann Rheum Dis. 2005;64:38-43.

23. Quan LD, Thiele GM, Tian J, Wang D. The development of novel therapies for rheumatoid arthritis. Expert Opinion on Therapeutic Patents. 2008;18(7):723-38.

24. Michael EW. Methotrexate in Rheumatoid Arthritis: A Quarter Century of Development. Trans Am Clin Climatol Assoc. 2013;124:16–25.

25. Maccagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac (‘Lodine’) compared with naproxen in patients with acute gout. Current medical research and opinion. 1991;12(7):423–9.

26. Weaver A, Chatwell R, Churchill M, Kastanek L, Beyene J, Garceau R, et al. Improved gastrointestinal tolerance and patient preference of enteric-coated sulfasalazine versus uncoated sulfasalazine tablets in patients with rheumatoid arthritis. Journal of clinical rheumatology: practical reports on rheumatic & musculoskeletal diseases. 1999;5(4):193–200.

27. Gaston G. A double-blind, randomized, parallel-group study of the pharmacokinetics and onset of action of Naprelan in patients following oral surgery. American journal of orthopedics (Bellevue, WA). 1996;25(9):37–41.

28. Altman R, Bosch B, Brune K, Patrignani P, Young C. Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology. Indian Drugs. 2015;75(8):859–77.

29. Peyman G.A. MINU LLC. Enhanced wound healing. U.S. Patent Application 12/144. 2008;182.

30. Prakash A, Jarvis B. Leflunomide. Indian Drugs, 1999;58(6):1137-64.

31. Graul Al. The year’s new drugs. Drug News Perspect. 2003;16:22–39.

32. Sibbald B. Rofecoxib (Vioxx) voluntarily withdrawn from the market. Canadian Medical Association Journal. 2004;171(9):1027–8.

33. Miner JrP, Placheta K, Orelmans E, Fort JG, Sostek M. Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg: a randomized, open-label, Phase I study in healthy volunteers. Alimentary pharmacology & therapeutics. 2010;32(3):414–24.

34. Bello AE. DUEXIS®(ibuprofen 800 mg, famotidine 26.6 mg: a new approach to gastroprotection for patients with chronic pain and inflammation who require treatment with a nonsteroidal anti-inflammatory drug. Therapeutic advances in musculoskeletal disease. 2012;4(5):327–39.

35. Choy EH, Kingsley GH, Panayi GS. Anti-CD4 monoclonal antibodies in rheumatoid arthritis. Springer Semin Immunopathol. 1998;20:261–73.

36. St Clair WE, van der Heijde DM, Smolen JS. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis Rheum. 2004;50:3432-43.

37. David SP. Advances in the Treatment of Rheumatoid Arthritis: Costs and Challenges. North Carolina Medical Journal. 2017;78(5):337–40.

38. https://www.centerwatch.com/drug-information/fda-approved-drugs/drug/737/enbrel-etanercept

39. Tanaka T, Hishitani Y, Ogata A. Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors. Biologics: targets & therapy. 2014;8:141.

40. Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. Journal of the American Society of Nephrology. 2002;13(2):559–75.

41. Ogale S, Hitraya E, Henk HI. Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC musculoskeletal disorders. 2002;12(1):204.

42. Chakraborty A, Tannenbaum S, Rordorf C, Lowe PJ, Floch D, Gram H, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. Clinical pharmacokinetics. 2012;51(6):1-18.

43. Khan MM. Monoclonal Antibodies as Therapeutic Agents. Immunopharmacology Springer. 2016;157-96.

44. Campbell L, Chen C, Bhagat SS, Parker RA, Oster AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology. 2010;50(3):552–62.

45. Hanada T, Yoshimura A. Regulation of cytokine signaling and inflammation. Cytokine & growth factor reviews. 2002;13(4-5):413–21.
46. Robbins PD, Evans CH, Chernajovsky Y. Gene therapy for arthritis. Gene Therapy. 2003;10(10):902.
47. Evans CH, Mankin HJ, Robbins PD, Ghiviziani SC, Herndon JH, Kang R, et al. Clinical Trial to Assess the Safety, Feasibility, and Efficacy of Transferring a Potentially Anti-Arthritic Cytokine Gene to Human Joints with Rheumatoid Arthritis. University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Human gene therapy. 1996;7(10):1261-80.
48. Baugh JA, Chitnis S, Donnelly SC, Monteiro J, Lin X, Plant BJ, et al. A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes and immunity. 2002;3(3):170.
49. Kim JM, Jeong IG, Ho SH, Hahn W, Park EJ, Kim S, et al. Protection against collagen-induced arthritis by intramuscular gene therapy with an expression plasmid for the interleukin-1 receptor antagonist. Gene therapy. 2003;10(18):1543.
50. Woods JM, Sitabkhan Y, Koch AE. Gene therapy for rheumatoid arthritis: recent advances. Current gene therapy. 2008;8(1):24-41.
51. Campbell IK, Bendele A, Smith DA, Hamilton JA. Granulocyte-macrophage colony-stimulating factor exacerbates collagen-induced arthritis in mice. Annals of the rheumatic diseases. 1997;56(6):364-8.
52. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, et al. Long-term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature medicine. 1996;2(5):551.
53. Palmer G, Gabay C. Interleukin-33 biology with potential insights into human diseases. Nature Reviews Rheumatology. 2011;7(6):321.
54. Wang H, Rickert M, Wieloch P, Lorenz E, Steck E, Richter W. Adenovirus-Mediated Gene Transfer of Human Growth and Differentiation Factor-5 (GDF-5) into the Healing Rat Achilles Tendon. Molecular Therapy. 2004;9(S1):S336.
55. Evans CH, Ghiviziani SC, Robbins PD. Arthritis gene therapy and its tortuous path into the clinic. Translational Research. 2013;161(4):205-16.
56. Goyal A, Kumar S, Nagpal M, Singh I, Arora S. Potential of novel drug delivery systems for herbal drugs. Ind J Pharm Educ Res. 2011;45:225-35.
57. Lee SM, Kim HJ, Ha YJ, Park YN, Lee SK, Park YB, et al. Targeted chemo-photothermal treatments of rheumatoid arthritis using gold half-shell multifunctional nanoparticles. ACS Nano. 2012;7(1):50-7.
58. Albuquerque J, Moura CC, Sarmento B, Reis S. Solid lipid nanoparticles: a potential multifunctional approach towards rheumatoid arthritis theranostics. Molecules. 2015;20(6):11103-18.
59. Lee SM, Kim HJ, Ha YJ, Park YN, Lee SK, Park YB, et al. Targeted chemo-photothermal treatments of rheumatoid arthritis using gold half-shell multifunctional nanoparticles. ACS Nano. 2013;7(1):50-7.
60. Satya PM, Padmaja NV, Nadiya S, Masthani S, Satya AK. A Review on Role of Nanoparticles in Rheumatoid arthritis therapy. Indian Journal of Research in Pharmacy and Biotechnology. 2016;4(6):255.
61. Lee H, Lee MY, Bhang SH, Kim BS, Kim YS, Ju JH, et al. Hyaluronate–gold nanoparticle/tocilizumab complex for the treatment of rheumatoid arthritis. ACS Nano. 2014;8(5):4790-8.
62. Homma A, Sato H, Okamachi A, Emura T, Ishizawa T, Kato T, et al. Novel hyaluronic acid-methotrexate conjugates for osteoarthritis treatment. Bioorganic & Medicinal chemistry. 2009;17(13):4647-56.
63. Zheng Z, Sun Y, Liu Z, Zhang M, Li C, Cai H. The effect of curcumin and its nanoformulation on adjuvant-induced arthritis in rats. Drug design, development, and therapy. 2015;9:4931.
64. Sailaja AK, Lola VS. Formulation of Mefenamic Acid Loaded Polymeric Nanoparticles for the Treatment of Rheumatoid Arthritis. Journal of Bionanoscience. 2018;12(2):177-83.
65. Zhou PH, Qiu B, Deng RH, Li HJ, Xu XF, Shang XF. Chondroprotective Effects of Hyaluronic Acid-Chitosan Nanoparticles Containing Plasmid DNA Encoding Cytokine Response Modifier A in a Rat Knee Osteoarthritis Model. Cellular Physiology and Biochemistry. 2018;47(3):1207-16.
66. Fan W, Li J, Yuan L, Chen J, Wang Z, Wang Y, G, et al. Intra-articular injection of kartogenin-conjugated polyurethane nanoparticles attenuates the progression of osteoarthritis. Drug delivery. 2018;25(1):1004-12.
67. Ye J, Wang Q, Zhou X, Zhang N. Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. International journal of pharmaceutics. 2008;352(1-2):273-9.
68. Boechat AL, de Oliveira CP, Tarrago AM, da Costa AG, Malheiro A, Gutierres SS, et al. Methotrexate-loaded lipid-core nanocapsules are highly effective in the control of inflammation in synovial cells and a chronic arthritis model. International journal of nanomedicine. 2015;10:6603.
69. Zhou M, Hou J, Zhong Z, Hao N, Lin Y, Li, C. Targeted delivery of hyaluronic acid-coated solid lipid nanoparticles for rheumatoid arthritis therapy. Drug delivery. 2018;25(1):716-22.
70. Metselaar JM, Van den Berg WB, Holthuysen AEM, Wauben MHM, Storm G, Van Lent PLEM. Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis. Annals of the rheumatic diseases. 2004;63(4):348-53.
71. Thulasiramaraju TV, Babu AS, Arunachalam A, Prathap M, Srikanth S, Sivaiah P. Liposome: A novel drug delivery system. International Journal of Biopharmaceutics. 2012;3(1):5-16.
72. Williams AS, Camilleri JP, Amos N, Williams BD. Differential effects of methotrexate and liposomally conjugated methotrexate in rat adjuvant-induced arthritis. Clinical & Experimental Immunology. 1995;102(3):560-5.
73. Metselaar J, Wauben MH, Wagenaar-Hilbers J, Boerman OC, Storm G. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis & Rheumatology. 2003;48(7):2059-66.
74. Prabhu P, Shetty R, Koland M, Vijayanarayana K, Vijay-
alakshmi KK, Nairy MH, et al. Investigation of nano lipid vesicles of methotrexate for anti-rheumatoid activity. International journal of nanomedicine. 2012;7:177.

Gottschalk O, Metz P, Dao Trong ML, Altenberger S, Jansson V, Mutschler W, et al. Therapeutic effect of methotrexate encapsulated in cationic liposomes (En-doMTX) in comparison to free methotrexate in an antigen-induced arthritis study in vivo. Scandinavian journal of rheumatology. 2015; 44(6):456-63.

Rahman M, Akhter S, Ahmad J, Ahmad MZ, Beg S, Ahmad FJ. Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy. Expert opinion on drug delivery. 2015; 12(4):635-52.

Jia M, Deng C, Luo J, Zhang P, Sun X., Zhang Z, et al. A novel dexamethasone-loaded liposome alleviates rheumatoid arthritis in rats. International journal of pharmaceutics. 2018;540(1-2):57-64.

Ho KS, Shoichet MS. Design considerations of polymeric nanoparticle micelles for chemotherapeutic delivery. Current Opinion in Chemical Engineering. 2013;2(1):53-9.

Singh Y, Meher JG, Raval K, Khan FA, Chaurasia M, Jain NK, et al. Nanoemulsion: Concepts, development, and applications in drug delivery. Journal of Controlled Release. 2017;252: 28-49.

Pey CM, Maestro A, Sole I, Gonzalez C, Solans C, Gutierrez JM, et al. Optimization of nano-emulsions prepared by low-energy emulsification methods at a constant temperature using a factorial design study. Colloids and Surfaces A: Physicochemical and Engineering Aspects. 2006;288(1-3): 144-50.

Shakeel F, Baboota S, Ahuja A, Ali J, Shafiq S. Celecoxib nanoemulsion: skin permeation mechanism and bioavailability assessment. Journal of drug targeting. 2008;16(10): 733-40.